The mainland suggests that qualified pieces of traditional Chinese medicine, proprietary Chinese medicine and traditional Chinese medicine preparations from medical institutions should be included in the catalogue of health insurance drugs. Chinese medicine stocks continued to be strong this morning. 02273.HK, which was listed on the market last month, rose as much as 9.1% to 44.6 yuan, a new high, and now rose 7% to 43.75 yuan, with 242000 shares traded, involving 10.55 million yuan. Chinese traditional medicine (00570.HK), once a high of 6.08 yuan in more than three years, is now at 5.77 yuan, up 11.6%, with a turnover of nearly 250 million yuan. Modern traditional Chinese medicine (01643.HK) rose 29.3% to 1.06 yuan, the highest for more than half a year since the first ten days of June last year, and now rose 22% to 1 yuan, with a transaction of 11.22 million yuan.
The initial stage of Tongrentang Technology (01666.HK) rose 10% to 9.22 yuan, the highest in more than two years, and now stands at 9.03 yuan, up 7.8%, with a transaction of 44.84 million yuan. Tongrentang National Medicine (03613.HK) rose 5.8% to 14.2 yuan, approaching the 52-week high set last Friday.
The early stage of Baiyunshan (00874.HK) rose 6% to 23.8 yuan, a five-month high, but now it is up less than 1% to 22.65 yuan. 01498.HK also rose 7.4%. Shenwei Pharmaceutical (02877.HK) reversed its weakness and is now down 2% at 6.75 yuan.
National Healthcare Security Administration and the State Administration of traditional Chinese Medicine recently issued the "guidance on Health Insurance to support the inheritance and innovative Development of traditional Chinese Medicine". It is stipulated that qualified pieces of traditional Chinese medicine, proprietary Chinese medicines and preparations of traditional Chinese medicine in medical institutions will be included in the list of medical insurance drugs. The equipment and use of proprietary Chinese medicines that have been included in the medical insurance catalogue negotiated by the state will be included in the monitoring and evaluation. Make full use of the "dual-channel" drug quality management mechanism, expand the channels for insured patients to designated retail pharmacies, and better protect the drug needs of the insured people.
According to the bearing capacity of the fund and clinical needs, all localities should bring qualified ethnic medicines, traditional Chinese medicine preparations from medical institutions and prepared pieces of traditional Chinese medicine into the scope of local medical insurance payment according to procedures, and establish a dynamic adjustment mechanism. The prepared slices of traditional Chinese medicine in accordance with the measures for the Administration of prescriptions and the regulations for the Administration of prepared slices of traditional Chinese Medicine in Hospitals but in excess of the commonly used doses prescribed in the Pharmacopoeia of the people's Republic of China will be included in the
In addition, CITIC issued a report at the end of last month, giving Gusheng Hall a "buy" rating for the first time, with a target price of HK $46 based on the valuation of 38 times next year's forecast price-to-earnings ratio. The company went public in December 2021 and became the first private Chinese medicine stock. According to the total revenue generated by providing medical and health solutions in 2020, the company is in a leading position among private providers of new traditional Chinese medicine medical and health services in China. The number of TCM doctors, offline medical institutions and urban coverage of offline institutions are the first in the industry. The core net profit of Gusheng Hall from 2021 to 2023 was 150 million yuan, 225 million yuan and 326 million yuan respectively.